Haploidentical NK Cell Infusion in Malignant Melanoma

Inclusion Criteria: * Histologically confirmed metastatic or relapsed malignant melanoma * Patients who received prior chemotherapy or immunotherapy * Patients who have at least one haploidentical donor willing to donate * ECOG performance status 0 or 1 * 18 - 75 years * At least one measurable disease according to the RECIST criteria * Patients with 45% or more left ventricular ejection fraction * Patients with 50% or more predicted DLCO * Adequate bone marrow function: absolute neutrophil count ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L; and hemoglobin ≥ 9 g/dL * Adequate liver function: total bilirubin ≤ 1.0 x upper limit of the normal range (ULN); AST/ALT ≤ 2.5 x ULN; and alkaline phosphatase ≤ 2.5 x ULN * Adequate renal function: serum creatinine ≤ 1.0 x ULN or creatinine clearance ≥ 60 mL/min/1.73m2 * At least 3 months of expected survival * Patients who signed informed consent Exclusion Criteria: * Patients who received other chemotherapeutic agents within 30 days prior to study enrollment * Patients who received adoptive cell therapy including hematopoietic stem cell transplantation * Patients infected with HIV, HBV, or HCV * Hypersensitivity to cyclophosphamide or interleukin-2 * Patients who received organ transplantation * Patients who had arrhythmia or ischemic heart disease * Pregnant or lactating women * Patients with uncontrolled infection who did not respond to appropriate antimicrobial agents